Mercer Global Advisors Inc. ADV Has $5.20 Million Stake in AstraZeneca PLC (NASDAQ:AZN)

Mercer Global Advisors Inc. ADV lifted its position in shares of AstraZeneca PLC (NASDAQ:AZNGet Rating) by 14.4% during the 4th quarter, HoldingsChannel reports. The fund owned 89,343 shares of the company’s stock after purchasing an additional 11,275 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in AstraZeneca were worth $5,204,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. OLD Mission Capital LLC bought a new position in AstraZeneca during the 3rd quarter worth $7,581,000. Venturi Wealth Management LLC raised its position in shares of AstraZeneca by 4.8% in the 3rd quarter. Venturi Wealth Management LLC now owns 21,689 shares of the company’s stock worth $1,303,000 after acquiring an additional 996 shares in the last quarter. Stephens Inc. AR raised its position in shares of AstraZeneca by 21.7% in the 3rd quarter. Stephens Inc. AR now owns 20,327 shares of the company’s stock worth $1,221,000 after acquiring an additional 3,621 shares in the last quarter. Commonwealth Equity Services LLC raised its position in shares of AstraZeneca by 13.1% in the 3rd quarter. Commonwealth Equity Services LLC now owns 161,626 shares of the company’s stock worth $9,707,000 after acquiring an additional 18,783 shares in the last quarter. Finally, Banque Cantonale Vaudoise raised its position in shares of AstraZeneca by 21.9% in the 3rd quarter. Banque Cantonale Vaudoise now owns 1,548 shares of the company’s stock worth $93,000 after acquiring an additional 278 shares in the last quarter. 20.54% of the stock is currently owned by institutional investors.

Shares of AstraZeneca stock traded down $0.27 during trading on Tuesday, hitting $68.34. The stock had a trading volume of 295,933 shares, compared to its average volume of 7,467,288. The firm has a market cap of $211.77 billion, a price-to-earnings ratio of 489.32, a P/E/G ratio of 1.30 and a beta of 0.48. AstraZeneca PLC has a 12 month low of $50.66 and a 12 month high of $71.70. The business’s 50-day moving average is $63.18 and its 200 day moving average is $60.18. The company has a current ratio of 1.16, a quick ratio of 0.76 and a debt-to-equity ratio of 0.72.

AstraZeneca (NASDAQ:AZNGet Rating) last announced its earnings results on Thursday, February 10th. The company reported $0.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.07. AstraZeneca had a net margin of 0.30% and a return on equity of 27.48%. The company had revenue of $11.50 billion during the quarter, compared to analyst estimates of $11.06 billion. During the same period in the previous year, the business earned $0.54 earnings per share. The firm’s quarterly revenue was up 55.2% compared to the same quarter last year. As a group, equities analysts expect that AstraZeneca PLC will post 3.31 EPS for the current year.

The firm also recently declared a semi-annual dividend, which was paid on Monday, March 28th. Shareholders of record on Friday, February 25th were given a dividend of $0.985 per share. This represents a yield of 2.4%. This is a positive change from AstraZeneca’s previous semi-annual dividend of $0.45. The ex-dividend date was Thursday, February 24th. AstraZeneca’s dividend payout ratio is presently 1,378.67%.

AZN has been the subject of a number of research analyst reports. Zacks Investment Research raised AstraZeneca from a “sell” rating to a “hold” rating and set a $61.00 target price for the company in a research report on Tuesday, January 4th. JPMorgan Chase & Co. lifted their price target on AstraZeneca from £100 ($130.11) to £120 ($156.13) in a research note on Thursday, April 7th. TheStreet upgraded AstraZeneca from a “c+” rating to a “b-” rating in a research note on Thursday, March 10th. Credit Suisse Group lifted their price target on AstraZeneca from GBX 9,000 ($117.10) to £110 ($143.12) in a research note on Friday, April 8th. Finally, DZ Bank upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Friday, February 11th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $6,669.29.

AstraZeneca Company Profile (Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Featured Stories

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNGet Rating).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.